Dr. Andrew Hill: “The first-line use of TDF/3TC/DTG leads to lower risks of clinical obesity than combinations like TAF/FTC/DTG or TAF/FTC/BIC, or dual therapies like DTG/3TC”
Dr. Andrew Hill, MD, is a senior visiting Research Fellow in the Pharmacology Department at Liverpool University. His main research is on antiretroviral treatment for developing countries. He is [...]
Dr. Nicolas Huot: “Predicting the exact timeline for the widespread implementation of therapies involving the reprogramming of Natural Killer cells for HIV prevention and treatment is challenging”
Nicolas Huot is a postdoc fellow in Dr. M.Müller-Trutwin Lab at the pasteur institut in PARIS , studying the role of NK cells in secondary lymphoid tissues [...]
Vicente Planelles: “Research in the field of senotherapeutics is still in its early stages, but initial results in the area of aging are highly encouraging”
Vicente Planelles, PhD, is a Professor in the Department of Pathology at the University of Utah and a member of the Cell Response and Regulation Program at [...]
Dr. Jean Michel – Molina: “For biomedical prevention of HIV we have a number of drugs which are likely to be available in the future: long acting drugs for prevention”
Jean-Michel Molina is Professor of Infectious Diseases at the University of Paris Diderot - Paris 7, France, and Head of the Infectious Diseases Department at the Saint-Louis [...]
Dra. Katharine Barr: “There are recent discoveries that support the development of new cure strategies”.
La Dra. Katharine Barr, quien participa en la sesión inaugural, nos habla sobre el reservorio del VIH y otras cuestiones relacionadas con los últimos avances y descubrimientos. [...]
Dr. Paul E. Sax: «We should continue to search for a cure as an aspirational goal”
El Dr. Paul Sax participa en la sesión inaugural del XIV Congreso de GeSIDA, con una ponencia titulada 'HAART, ART, 2DR, LA-ART.... What acronym is next?'. Nos [...]